A cancer treatment modality that prioritises QoL, with Ben Z...
Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.
Newsletters and Deep Dive digital magazine
Immuneering's Ben Zeskind explains how, by focusing on quality of life as well as quantity, they've created a drug for pancreatic cancer.
Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Senti Bio's Tim Lu discusses “logic-gated” cells, which have multiple receptors allowing them to attack cancer cells while leaving healthy cells alone
A new technology just announced this weekend in a paper in Nature could have a radical impact on how gene assembly is carried out.
Immunis CEO Hans Keirstead explains why his company thinks the immune system is key to tackling healthspan and longevity.
Editor's Picks
Newsletters and Deep Dive
digital magazine